Thromboprophylaxis for patients with coronary artery disease and atrial fibrillation (AF) is problematic when there is a low or moderate risk of stroke (CHADS2 score=0 or 1), particularly when patients experience an acute coronary syndrome or undergo intracoronary stent implantation. Some physicians may be reluctant to prescribe oral anticoagulation (OAC) in these patients and several recent guidelines propose slightly different management in such settings [1,2]. Our goal was to evaluate whether treatment with an OAC is appreciably beneficial in these AF patients.
